Cancers, Vol. 16, Pages 1481: EMP2 Serves as a Functional Biomarker for Chemotherapy-Resistant Triple-Negative Breast Cancer
In this study, the expression of the tetraspan protein epithelial membrane protein 2 (EMP2) was explored as a predictor of TNBC response to standard chemotherapy. We demonstrate that EMP2 functions as a prognostic biomarker for patients treated with taxane-based chemotherapy, with high expression at both transcriptomic and protein levels following treatment correlating with poor overall survival. Moreover, we show that targeting EMP2 in combination with docetaxel reduces tumor load in syngeneic and xenograft models of TNBC. These results provide support for the prognostic and therapeutic potential of this tetraspan protein...
Source: Cancers - April 12, 2024 Category: Cancer & Oncology Authors: Ann M. Chan Brian Aguirre Lucia Liu Vei Mah Justin M. Balko Jessica Tsui Navin P. Wadehra Neda A. Moatamed Mahdi Khoshchehreh Christen M. Dillard Meagan Kiyohara Yahya Elshimali Helena R. Chang Diana Marquez-Garban Nalo Hamilton Richard J. Pietras Lynn K. Tags: Article Source Type: research
Ganoderma spore lipid ameliorates docetaxel, cisplatin, and 5-fluorouracil chemotherapy-induced damage to bone marrow mesenchymal stem cells and hematopoiesis
A triplet chemotherapy regimen of docetaxel, cisplatin, and 5-fluorouracil (TPF) is used to treat head and neck squamous cell carcinoma; however, it is toxic to bone marrow mesenchymal stem cells (BMSCs). We p... (Source: BMC Complementary and Alternative Medicine)
Source: BMC Complementary and Alternative Medicine - April 12, 2024 Category: Complementary Medicine Authors: Haohui Lin, Manhon Chung, Jingchun Sun, Yi Yang, Li Zhang, Xiaohua Pan, Minghui Wei, Sa Cai and Yu Pan Tags: Research Source Type: research
Short-term efficacy and safety of neoadjuvant pyrotinib plus taxanes for early HER2-positive breast cancer: a single-arm exploratory phase II trial
CONCLUSIONS: In female patients with HER2-positive non-metastatic BC, neoadjuvant pyrotinib monotherapy plus taxanes appears to show promising clinical benefit and controllable AEs [Chinese Clinical Trial Registry (ChiCTR2100050870)]. The long-term efficacy and safety of this regime warrant further verification.PMID:38601287 | PMC:PMC11002487 | DOI:10.21037/gs-24-38 (Source: Hand Surgery)
Source: Hand Surgery - April 11, 2024 Category: Surgery Authors: Guolin Ye Peixian Chen Xiangwei Liu Tiancheng He Xavier Pivot Ruilin Pan Dan Zhou Lewei Zhu Kun Zhang Wei Li Shuqing Yang Jiawei Lin Gengxi Cai Huiqi Huang Source Type: research
Short-term efficacy and safety of neoadjuvant pyrotinib plus taxanes for early HER2-positive breast cancer: a single-arm exploratory phase II trial
CONCLUSIONS: In female patients with HER2-positive non-metastatic BC, neoadjuvant pyrotinib monotherapy plus taxanes appears to show promising clinical benefit and controllable AEs [Chinese Clinical Trial Registry (ChiCTR2100050870)]. The long-term efficacy and safety of this regime warrant further verification.PMID:38601287 | PMC:PMC11002487 | DOI:10.21037/gs-24-38 (Source: Hand Surgery)
Source: Hand Surgery - April 11, 2024 Category: Surgery Authors: Guolin Ye Peixian Chen Xiangwei Liu Tiancheng He Xavier Pivot Ruilin Pan Dan Zhou Lewei Zhu Kun Zhang Wei Li Shuqing Yang Jiawei Lin Gengxi Cai Huiqi Huang Source Type: research
Real-world retrospective study of prostate-specific antigen and safety assessment with darolutamide plus androgen deprivation therapy for metastasis hormone-sensitive prostate cancer
CONCLUSIONS: For treating prostate cancer, DARO with ADT has good early efficacy, demonstrating prompt and substantial control of PSA levels, with a favorable safety profile.PMID:38590967 | PMC:PMC10999023 | DOI:10.21037/tau-24-96 (Source: Cancer Control)
Source: Cancer Control - April 9, 2024 Category: Cancer & Oncology Authors: Jia Liu Shenghan Wang Yong Yang Shuo Wang Davide Campobasso Yu Guang Tan Qiang Gao Lin Yang Yudong Cao Yongpeng Ji Peng Du Bao Zhang Source Type: research
Current Systemic Therapy in Men with Metastatic Castration-Sensitive Prostate Cancer
AbstractPurpose of ReviewThis review aims to explore the evolving landscape of treatments available for metastatic castration-sensitive prostate cancer (mCSPC) patients.Recent FindingsIn less than a decade, evidence was chronologically provided that (1) systemic treatment intensification with docetaxel improves outcomes, including survival, in men with mCSPC, (2) then that these outcomes are also improved when a second-generation androgen receptor pathway inhibitor (ARPI) is combined with androgen deprivation therapy (ADT), and (3) using a “triplet systemic therapy,” which consists in the combination of ADT, an ARPI an...
Source: Current Oncology Reports - April 9, 2024 Category: Cancer & Oncology Source Type: research
Risk of recurrence after neoadjuvant chemotherapy and transoral robotic surgery in patients with oropharynx cancer that avoid adjuvant radiation
CONCLUSION: Our findings suggest that pathology-based risk-adapted omission of adjuvant treatment following NAC + S does not appear to elevate recurrence risk and that NAC may identify patients with favorable tumor biology, yielding a 2-year RFS probability exceeding 95% without adjuvant treatment. Further, the study identifies a patient subset experiencing disease recurrence despite triple modality therapy. Despite limitations, including a retrospective design and modest sample size, the data advocate for controlled NAC + S studies.PMID:38581118 | DOI:10.1002/cam4.7146 (Source: Cancer Control)
Source: Cancer Control - April 6, 2024 Category: Cancer & Oncology Authors: Alisha R Pershad Punam G Thakkar Joseph F Goodman Arjun Joshi Seth M Steinberg Clint T Allen Charalampos S Floudas Source Type: research
Impact of disease volume on survival efficacy of triplet therapy for metastatic hormone-sensitive prostate cancer: a systematic review, meta-analysis, and network meta-analysis
CONCLUSIONS: Triplet therapy improves OS in mHSPC patients compared to docetaxel-based doublet therapy, irrespective of disease volume. However, based on treatment ranking, triplet therapy should preferably be considered for patients with high-volume mHSPC while those with low-volume are likely to be adequately treated with ARSI + ADT.PMID:38582807 | DOI:10.1007/s10147-024-02485-4 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - April 6, 2024 Category: Cancer & Oncology Authors: Akihiro Matsukawa Pawel Rajwa Tatsushi Kawada Kensuke Bekku Ekaterina Laukhtina Jakob Klemm Benjamin Pradere Keiichiro Mori Pierre I Karakiewicz Takahiro Kimura Piotr Chlosta Shahrokh F Shariat Takafumi Yanagisawa Source Type: research
Risk of recurrence after neoadjuvant chemotherapy and transoral robotic surgery in patients with oropharynx cancer that avoid adjuvant radiation
ConclusionOur findings suggest that pathology-based risk-adapted omission of adjuvant treatment following NAC + S does not appear to elevate recurrence risk and that NAC may identify patients with favorable tumor biology, yielding a 2-year RFS probability exceeding 95% without adjuvant treatment. Further, the study identifies a patient subset experiencing disease recurrence despite triple modality ther apy. Despite limitations, including a retrospective design and modest sample size, the data advocate for controlled NAC + S studies. (Source: Cancer Medicine)
Source: Cancer Medicine - April 6, 2024 Category: Cancer & Oncology Authors: Alisha R. Pershad,
Punam G. Thakkar,
Joseph F. Goodman,
Arjun Joshi,
Seth M. Steinberg,
Clint T. Allen,
Charalampos S. Floudas Tags: BRIEF COMMUNICATION Source Type: research
Impact of disease volume on survival efficacy of triplet therapy for metastatic hormone-sensitive prostate cancer: a systematic review, meta-analysis, and network meta-analysis
ConclusionsTriplet therapy improves OS in mHSPC patients compared to docetaxel-based doublet therapy, irrespective of disease volume. However, based on treatment ranking, triplet therapy should preferably be considered for patients with high-volume mHSPC while those with low-volume are likely to be adequately treated with ARSI + ADT. (Source: International Journal of Clinical Oncology)
Source: International Journal of Clinical Oncology - April 6, 2024 Category: Cancer & Oncology Source Type: research
CLO24-081: Induction Chemotherapy in Locally Advanced Squamous Cell Carcinoma of Head and Neck-Biweekly Docetaxel, Cisplatin, 5-Fluorouracil, Leucovorin (TPFL) Versus Triweekly TPF: Response Assessment and Translation Into Survival Benefit
J Natl Compr Canc Netw. 2024 Apr 5;22(2.5):CLO24-081. doi: 10.6004/jnccn.2023.7186.NO ABSTRACTPMID:38580290 | DOI:10.6004/jnccn.2023.7186 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - April 5, 2024 Category: Cancer & Oncology Authors: Sreevalli Anantharamu A Sreevalli Linu Abraham Jacob Lokanatha Dasappa Suresh Babu Mc Iokesh Kn Rudresha Ah R Lakkavalli Krishnappa Saldanha Saldanha Source Type: research
91 Real World data, tolerability, and clinical outcomes in patients with advanced NSCLC treated with Sotorasib in University Hospitals Birmingham
KRAS G12C mutation is the second most prevalent oncogenic driver in non-squamous NSCLC. Sotorasib is a potent selective oral inhibitor for treating KRAS G12C mutation-in positive locally advanced or metastatic NSCLC patients whose disease has progressed on, or who cannot tolerate platinum-based chemotherapy or anti PD-1/PD-L1 immunotherapy. It has been approved to use in the second line by NHS England since late 2021. The approval comes from CodeBreak100 Phase 2 Trial (showed complete response in 3.2% and partial response in 33.9%) and from indirect comparisons that showed it to be superior in OS and PFS compared with doce...
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Rubab Batool, Avisek Datta, Qamar Ghafoor, Watkins Steven Tags: NSCLC Systemic Treatment Source Type: research
Docetaxel, cyclophosphamide, and epirubicin: application of PBPK modeling to gain new insights for drug-drug interactions
In conclusion, the PBPK models can be used to further investigate the DDI potential of each drug and to develop dosage recommendations for concurrent usage by additional perpetrators or victims.Graphical abstract (Source: Journal of Pharmacokinetics and Pharmacodynamics)
Source: Journal of Pharmacokinetics and Pharmacodynamics - March 30, 2024 Category: Drugs & Pharmacology Source Type: research
